Skip to main content

Advertisement

SpringerLink
Log in

The new epidemiology of hepatitis B in the United States

  • Published:
Current Hepatitis Reports Aims and scope Submit manuscript

Abstract

Although the incidence of hepatitis B virus (HBV) in the United States is decreasing, it remains an important health issue, with nearly 2 million people currently infected and a 7% to 30% lifetime mortality rate. Vaccination has markedly decreased the number of acute HBV cases, especially in children and adolescents; however, there continues to be a substantial incidence of new infections in intravenous drug users and persons with high-risk sexual behavior and of newly recognized disease in immigrants. Perinatal transmission has been significantly reduced with universal infant vaccination, and transfusion/iatrogenic infection has been nearly eradicated by screening blood products and vaccinating at-risk medical professionals. HBV infection rates vary with respect to racial and geographic distribution as well as known risk factors. The Asian/Pacific Islander population continues to have the highest rate (prevalence) of infection in the United States. Further advances in screening and vaccination must be made to further reduce the incidence and prevalence of HBV in the United States.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Gish RG, Gadano AC: Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006, 13:787–798.

    Article  PubMed  CAS  Google Scholar 

  2. Cohen C, Evans AA, London WT, et al.: Underestimation of chronic hepatitis B virus infection in the United States of America. J Viral Hepat 2008, 15:12–13.

    PubMed  CAS  Google Scholar 

  3. Centers for Disease Control and Prevention (CDC): Surveillance for acute viral hepatitis. MMWR Morb Mortal Wkly Rep 2008, 57:SS–S2.

    Google Scholar 

  4. Centers for Disease Control and Prevention (CDC): A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); part 2: immunization of adults. MMWR Morb Mortal Wkly Rep 2005, 55:1–33.

    Google Scholar 

  5. Kim WR, Benson JT, Therneau TM, et al.: Changing epidemiology of hepatitis B in a U.S. community. Hepatology 2004, 39:811–816.

    Article  PubMed  Google Scholar 

  6. Centers for Disease Control and Prevention (CDC): Screening for chronic hepatitis B among Asian/Pacific Islander populations—New York City, 2005. MMWR Morb Mortal Wkly Rep 2006, 55:505–509.

    Google Scholar 

  7. Sherman A, Tsang T, Villaneuva G, et al.: Mass screenings in New York City reveal extraordinarily high prevalence of hepatitis B in an urban Asian population. Hepatology 2005, 42(Suppl 1):214A.

    Google Scholar 

  8. Alter MJ: Epidemiology and prevention of hepatitis B. Semin Liver Dis 2003, 23:39–46.

    Article  PubMed  Google Scholar 

  9. Centers for Disease Control and Prevention (CDC): A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP); part 1: immunization of infants, children, and adolescents. MMWR Morb Mortal Wkly Rep 2005, 54:1–23.

    Google Scholar 

  10. Li X, Yang Y, Hou H, et al.: Interruption of HBV intrauterine transmission: a clinical study. World J Gastroenterol 2003, 9:1501–1503.

    PubMed  CAS  Google Scholar 

  11. Backmund M, Meyer K, Scheutz C, Reimer J: Factors associated with exposure to hepatitis B virus in injection drug users. Drug Alcohol Depend 2006, 84:154–159.

    Article  PubMed  Google Scholar 

  12. Centers for Disease Control and Prevention (CDC): Newborn hepatitis B vaccination coverage among children born January 2003–June 2005—United States. MMWR Morb Mortal Wkly Rep 2008, 57:825–828.

    Google Scholar 

  13. Lavanchy D: Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97–107.

    Article  PubMed  CAS  Google Scholar 

  14. Kuo I, Sherman SG, Thomas DL, Strathdee SA: Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend 2004, 1:69–78.

    Article  Google Scholar 

  15. Lum PJ, Hahn JA, Shafer KP, et al.: Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. J Viral Hepat 2008, 15:229–236.

    PubMed  CAS  Google Scholar 

  16. Judd A, Hickman M, Hope VD, et al.: Twenty years of selective hepatitis B vaccination: is hepatitis B declining among injecting drug users in England and Wales? J Viral Hepat 2007, 14:584–591.

    Article  PubMed  CAS  Google Scholar 

  17. Des Jarlais DC, Fisher DG, Newman JC, et al.: Providing hepatitis B vaccination to injection drug users: referral to health clinics vs. on-site vaccination at a syringe exchange program. Am J Public Health 2001, 91:1791–1792.

    Article  PubMed  Google Scholar 

  18. Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48:353–367.

    Article  PubMed  CAS  Google Scholar 

  19. Alberti A, Clumeck N, Collins S, et al.: Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005, 42:615–624.

    Article  PubMed  Google Scholar 

  20. McGovern BH: The epidemiology, natural history, and prevention of hepatitis B: implications of HIV coinfection. Antivir Ther 2007, 12(Suppl 3):H3–H13.

    Google Scholar 

  21. Thio CL: Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis 2003, 23:125–136.

    Article  PubMed  CAS  Google Scholar 

  22. Raj RR, Mathur A, Udawat HP, et al.: Prevalence of occult hepatitis B and C in HIV patients infected through sexual transmission. Trop Gastroenterol 2007, 28:19–23.

    Google Scholar 

  23. Flores YN, Yee HF, Leng M, et al.: Risk factors for chronic liver disease in blacks, Mexican Americans, and whites in the United States: results from NHANES IV, 1999–2004. Am J Gastroenterol 2008, 103:2231–2238.

    Article  PubMed  Google Scholar 

  24. US Census Bureau website. Available at www.census.gov. Accessed August 31, 2008.

  25. Fisher DG, Reynolds GL, Jaffe A, Perez MJ: Hepatitis and human immunodeficiency virus co-infection among injection drug users in Los Angeles County, California. J Addict Dis 2006, 25:25–32.

    Article  PubMed  Google Scholar 

  26. Chu CJ, Keeffe EB, Han SH, et al.: Hepatitis B genotypes in the United States: results of a nationwide study. Gastroenterology 2003, 125:444–451.

    Article  PubMed  Google Scholar 

  27. Centers for Disease Control and Prevention (CDC): Characteristics of persons with chronic hepatitis B—San Francisco, California 2006. MMWR Morb Mortal Wkly Rep 2007, 56:446–448.

    Google Scholar 

  28. Lin SY, Chang ET, So SK: Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology 2007, 47:1034–1040.

    Article  Google Scholar 

  29. Hann HL, Hann RS, Maddrey WC: Hepatitis B virus infection in 6130 unvaccinated Korean-Americans surveyed between 1988 and 1990. Am J Gastroenterol 2007, 102:767–772.

    Article  PubMed  Google Scholar 

  30. Hu K: Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol 2008, 103:1824–1833.

    Article  PubMed  Google Scholar 

  31. Hutton DW, Tan D, So SK, Brandeau ML: Cost-effectiveness of screening and vaccinating Asian and Pacific Islander adults for hepatitis B. Ann Intern Med 2007, 147:460–469.

    PubMed  Google Scholar 

  32. Kobayashi M, Akuta N, Suzuki F, et al.: Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C. J Med Virol 2006, 78:60–67.

    Article  PubMed  Google Scholar 

  33. Chan HL, Hui AY, Wong ML, et al.: Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004, 53:1494–1498.

    Article  PubMed  Google Scholar 

  34. Yang H, Yeh S, Chen P, et al.: Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst 2008, 100:1134–1143.

    Article  PubMed  CAS  Google Scholar 

  35. Gish RG, Locarnini S: Genotyping and genomic sequencing in clinical practice. Clin Liver Dis 2007, 11:761–795.

    Article  PubMed  Google Scholar 

  36. Chu CJ, Keeffe EB, Han SH, et al.: Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003, 38:619–628.

    Article  PubMed  CAS  Google Scholar 

  37. Keeffe EB, Dietrich DT, Han SB, et al.: A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006, 4:936–962.

    Article  PubMed  CAS  Google Scholar 

  38. Torbenson M, Kannangai R, Astemborski J, et al.: High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004, 39:51–57.

    Article  PubMed  Google Scholar 

  39. Shetty K, Hussain M, Nei L, et al.: Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008, 14:534–540.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. California Pacific Medical Center, 2340 Clay Street, Third Floor, San Francisco, CA, 94115, USA

    Catherine T. Frenette

Authors
  1. Catherine T. Frenette
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert G. Gish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine T. Frenette.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Frenette, C.T., Gish, R.G. The new epidemiology of hepatitis B in the United States. Curr hepatitis rep 8, 3–9 (2009). https://doi.org/10.1007/s11901-009-0001-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-009-0001-2

Keywords

Search

Navigation